We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Monte Rosa Therapeutics (NASDAQ:GLUE) currently has a cash runway of 3.9 years, based on its cash reserves of US$242m and an annual cash burn of US$63m as of September 2024. The company has also significantly reduced its cash burn by 49% year-on-year. While its cash burn relative to market capitalization is about 16%, suggesting potential dilution if more cash is raised, the overall assessment is that the company is managing its spending effectively and has sufficient funds for its medium-term needs.
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP significantly reduced its stake in Monte Rosa Therapeutics ($GLUE) by selling over 150,000 shares in Q3, while other major institutions increased their holdings. Monte Rosa Therapeutics' CEO also sold shares in January. The stock currently trades near $19, and analysts have a "Moderate Buy" consensus rating with an average price target of $31.33.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update
Monte Rosa Therapeutics (NASDAQ: GLUE) saw a significant increase in short interest in January, with shares sold short rising by 38.0% to 7,664,016, representing approximately 12.6% of the company's shares. Despite this, analyst sentiment remains largely positive, with an average "Moderate Buy" rating and a target price of $31.33. The company's CEO also sold a portion of their shares in early January, while institutional investors hold nearly 80% of the stock.
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%
Monte Rosa Therapeutics (NASDAQ:GLUE) shares have recently fallen by 26%, despite previous strong performance, leading to a low price-to-sales (P/S) ratio of 7.8x compared to the biotech industry average. Analysts predict a significant revenue decline of 43% annually over the next three years, contrasting sharply with the industry's projected 141% growth. This negative outlook on future revenue growth explains the company's currently low P/S ratio and suggests limited prospects for a drastic stock price increase without substantial improvement in its top-line performance.
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%
Monte Rosa Therapeutics (NASDAQ:GLUE) shares have fallen 26% in the last month, despite a 164% gain over the past year. The company's price-to-sales (P/S) ratio of 7.8x is lower than the industry average, potentially indicating investor concern over future revenue growth, as analysts forecast a 43% annual revenue decline over the next three years, contrasting sharply with the industry's projected 141% growth.
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains
Institutional investors in Monte Rosa Therapeutics (NASDAQ:GLUE) experienced a 12% loss last week, causing the company's market cap to drop by US$195 million. Despite this, these investors have seen a significant 175% one-year return, softening the recent blow. Institutions, holding 52% of the company, and hedge funds, owning 21%, exert substantial influence, potentially affecting the stock's future performance.
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold
Zacks Research has downgraded Monte Rosa Therapeutics (NASDAQ:GLUE) from a "strong-buy" to a "hold" rating. Despite this, other firms like Wedbush and Piper Sandler maintain "outperform" or "overweight" ratings with higher price targets. The company recently beat earnings estimates, but its CEO sold a significant number of shares in early January.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Nine brokerages have given Monte Rosa Therapeutics (NASDAQ:GLUE) a consensus "Moderate Buy" rating, with an average 12-month price target of $31.33. The company recently surpassed earnings expectations, reporting an EPS of ($0.33) against a ($0.39) consensus. Insider trading shows CEO Markus Warmuth sold 5,466 shares, reducing his holding by 0.88%, while institutional investors hold nearly 80% of the stock.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest
Monte Rosa Therapeutics (NASDAQ:GLUE) experienced a significant 34.3% decrease in short interest in January, totaling 5,554,802 shares as of January 15th. This leaves about 9.1% of shares shorted and a days-to-cover ratio of 1.4. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $31.33.
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9% - What's Next?
Monte Rosa Therapeutics (NASDAQ:GLUE) experienced a 6.9% decline in its stock price during intraday trading, with shares falling to $21.51 on significantly lower volume than usual. Despite this recent dip, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $31.33. The company recently surpassed quarterly earnings and revenue estimates and has a market capitalization of approximately $1.38 billion, with institutional investors holding a substantial portion of its stock.
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC has acquired a new stake of 51,133 shares in Monte Rosa Therapeutics (NASDAQ:GLUE), valued at approximately $379,000, bringing their total holding to about 0.08%. This purchase contributes to institutional investors owning nearly 80% of the stock. Monte Rosa Therapeutics recently surpassed earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $31.33.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-8102 Phase 1 Interim Data
Monte Rosa Therapeutics (GLUE) recently announced positive interim Phase 1 data for MRT-8102, which has led to significant share price growth. Despite a high Price-to-Earnings (P/E) ratio of 92.4x suggesting overvaluation compared to peers and industry averages, a Discounted Cash Flow (DCF) model indicates the stock is about 20% undervalued. This discrepancy creates a dilemma for investors regarding future buying opportunities and the balance between current profitability expectations and long-term potential.
Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering
Latham & Watkins LLP advised the underwriters in Monte Rosa Therapeutics' underwritten public offering, which is expected to raise approximately US$300 million. Monte Rosa, a clinical-stage biotechnology company, sold 11,125,000 shares of its common stock and pre-funded warrants for 1,375,000 shares. The offering is anticipated to close around January 12, 2026.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-8102 Phase 1 Interim Data
Monte Rosa Therapeutics (GLUE) recently announced positive interim Phase 1 data for its drug MRT-8102, showing strong target engagement and a favorable safety profile, which has driven significant stock price increases. Despite a high Price-to-Earnings ratio of 92.4x suggesting overvaluation compared to peers and industry averages, a Discounted Cash Flow (DCF) model indicates the stock might be undervalued by approximately 20%. This creates a tension for investors between earnings-based multiples and future cash flow projections.
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise
Monte Rosa Therapeutics recently announced positive interim Phase 1 data for its NEK7-directed degrader MRT-8102, which showed deep NEK7 degradation and broad reductions in inflammatory markers. This promising data, coupled with a US$300 million follow-on equity offering, strengthens the company's financial position and pipeline future. While the stock has seen a significant move, dilution and upcoming lock-up expiries are important short-term factors for investors to consider.
Goodwin Guides Monte Rosa Therapeutics In Pricing Of $300 Million Underwritten Public Offering
Goodwin Procter LLP advised Monte Rosa Therapeutics, Inc. on the pricing of an underwritten public offering of its common stock and pre-funded warrants, which is expected to raise approximately $300 million. Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing molecular glue degrader (MGD) medicines for various serious diseases, utilizing its QuEEN™ discovery engine. The offering included 11,125,000 shares of common stock and pre-funded warrants for 1,375,000 shares, with an option for underwriters to purchase additional shares.
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise
Monte Rosa Therapeutics recently completed a $300 million equity offering after releasing positive interim Phase 1 data for its NEK7-directed degrader MRT-8102. This data showed deep NEK7 degradation and reduced inflammatory markers, suggesting potential for both systemic and CNS inflammation treatment. While the capital raise and clinical data strengthen Monte Rosa's near-term outlook, shareholders should be aware of dilution risks, lock-up expiries, and potential future trial setbacks.
Monte Rosa Therapeutics (GLUE) Price Target Increased by 30.77% to 28.49
The average one-year price target for Monte Rosa Therapeutics (GLUE) has been increased by 30.77% to $28.49 per share from the previous estimate of $21.78. This new target is an average of analyst estimates, ranging from $17.17 to $38.85 per share, and represents an 18.75% increase from the latest closing price of $23.99. Institutional ownership data shows 287 funds holding positions, with key shareholders including NEA Management Company, Bvf, and Versant Venture Management.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a consensus "Moderate Buy" recommendation from eight brokerages, with an average one-year target price of $30.20. The positive sentiment is driven by strong interim Phase I clinical data for MRT‑8102, which showed deep NEK7 degradation and an 85% reduction in CRP, leading to significant stock rallies and bullish analyst upgrades. However, the company recently announced a $300 million public offering, introducing potential share dilution.
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics, Inc. announced the pricing of an underwritten public offering to raise approximately $300 million. The offering includes 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants for 1,375,000 shares at $23.9999 per warrant. The company has also granted underwriters an option to purchase an additional 1,875,000 shares.
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics, Inc. announced the pricing of an underwritten public offering expected to generate approximately $300 million in gross proceeds. The offering includes 11,125,000 shares of common stock at $24.00 per share and 1,375,000 pre-funded warrants. The company also granted underwriters a 30-day option to purchase additional shares, with the offering expected to close around January 12, 2026.
Experimental pill slashes key heart inflammation marker in early trial
Monte Rosa Therapeutics (GLUE) announced positive interim Phase 1 data for its experimental drug MRT-8102, showing an 85% reduction in hsCRP, a key heart inflammation marker, in high cardiovascular disease (CVD) risk subjects. The oral molecular glue degrader demonstrated a strong safety profile and significant NEK7 degradation, leading to a substantial positive market reaction for GLUE stock. The company plans a Phase 2 study for atherosclerotic cardiovascular disease (ASCVD) in 2026 and expects further GFORCE-1 study results in H2 2026.
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares
Monte Rosa Therapeutics CEO Markus Warmuth sold 5,466 shares of GLUE stock for $128,396 on January 7th, reducing his direct ownership by 0.88%. This sale followed a significant stock rally and analyst upgrades due to positive Phase I data for MRT-8102, which showed deep NEK7 degradation and 85% CRP reduction. However, the company also priced a $300 million underwritten offering, leading to dilution concerns.
Monte Rosa Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler
Monte Rosa Therapeutics has entered into an underwriting agreement with Jefferies, TD Securities, and Piper Sandler for a public offering of common stock and pre-funded warrants. The offering involves 11,125,000 shares at $24.00 per share and 1,375,000 pre-funded warrants at $23.9999, with an option for underwriters to purchase additional shares. The company expects net proceeds of approximately $281.6 million, which will be used to fund the development of MRT-8102, its QuEEN platform, additional degrader programs, and general corporate purposes.
Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering
Latham & Watkins LLP advised the underwriters in Monte Rosa Therapeutics' underwritten public offering, which is expected to raise approximately US$300 million before deductions. Monte Rosa Therapeutics, a clinical-stage biotechnology company, priced 11,125,000 shares of common stock at US$24 per share and pre-funded warrants for 1,375,000 shares at US$23.9999 per warrant. The offering, which includes a 30-day option for underwriters to purchase additional shares, is anticipated to close around January 12, 2026.
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares
Monte Rosa Therapeutics (GLUE) has priced an underwritten public offering to raise approximately $300 million. The offering includes 11.125 million shares at $24 per share and pre-funded warrants for 1.375 million shares at $23.999 per warrant. The company also granted underwriters an option to purchase an additional 1.875 million shares.
Biotech Monte Rosa is selling $300M in new shares to investors
Monte Rosa Therapeutics announced the pricing of an underwritten public offering to sell 11,125,000 common shares at $24.00 per share and 1,375,000 pre-funded warrants at $23.9999 each, aiming to raise approximately $300 million. The company has also granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. This offering, expected to close around January 12, 2026, follows a series of positive clinical updates and financing announcements that have recently led to significant stock price gains.
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics has announced the pricing of a $300 million underwritten public offering, including common stock at $24.00 per share and pre-funded warrants at $23.9999. The offering comprises 11,125,000 shares of common stock and 1,375,000 pre-funded warrants, with an option for underwriters to purchase an additional 1,875,000 shares. The proceeds will support the clinical-stage biotechnology company's development of molecular glue degrader-based medicines.
Monte Rosa Therapeutics prices $300 million public offering
Monte Rosa Therapeutics (NASDAQ: GLUE) has priced an underwritten public offering to raise approximately $300 million in gross proceeds. The offering includes common stock and pre-funded warrants, with underwriters having an option for additional shares. This comes as the company's stock trades near its 52-week high, despite an InvestingPro analysis suggesting it may be overvalued.
Monte Rosa Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics, Inc. announced the pricing of a public offering expected to raise approximately $300 million. The offering includes 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants for 1,375,000 shares at $23.9999 each. The company also granted underwriters a 30-day option to purchase an additional 1,875,000 shares, with the offering anticipated to close around January 12, 2026.
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a proposed underwritten public offering of $200.0 million in common stock and pre-funded warrants. The clinical-stage biotechnology company also plans to grant underwriters a 30-day option to purchase an additional $30.0 million in common stock. The offering is subject to market conditions and is being managed by Jefferies, TD Cowen, and Piper Sandler as joint book-running managers.
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Its Strong 1 Year Share Price Momentum
Monte Rosa Therapeutics (GLUE) has seen significant share price momentum, with a 288.65% one-year return, prompting a reassessment of its valuation. Despite trading at a high Price-to-Earnings ratio of 72.4x, suggesting overvaluation compared to peers, a Discounted Cash Flow (DCF) model indicates the stock is undervalued by 37.8%. The divergence between these valuation methods highlights the complexity in determining the company's true value, especially given declining revenue and net income.
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced an underwritten public offering of $200.0 million worth of common stock and pre-funded warrants. The company also plans to grant underwriters a 30-day option to purchase an additional $30.0 million in common stock. The offering is subject to market conditions and is being managed by Jefferies, TD Cowen, and Piper Sandler as joint book-running managers.
Biotech working on new medicines moves to raise $200M
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a proposed underwritten public offering to raise $200 million through common stock and pre-funded warrants, with underwriters having an option for an additional $30 million. This move follows a period of positive clinical updates and corporate milestones, including favorable data for its drug candidates MRT-2359 and MRT-8102, as well as collaboration progress with Novartis. The offering is subject to market conditions and is being made under an existing shelf registration statement.
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - Should You Buy?
Monte Rosa Therapeutics (NASDAQ:GLUE) reached a new 52-week high of $23.90, trading significantly above its previous close of $16.01 on heavy volume. Despite beating recent earnings estimates, the stock's current trading price is above the consensus analyst target of $17.75, which suggests a "Hold" rating from analysts. The company, focused on AI-driven drug discovery, maintains a $1.57 billion market cap with substantial institutional ownership but faces a forecasted negative FY EPS.
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics (Nasdaq: GLUE) has announced a proposed underwritten public offering of $200.0 million in common stock and pre-funded warrants, with an option for underwriters to purchase an additional $30.0 million in common stock. The offering is contingent on market conditions and subject to regulatory approvals. Jefferies, TD Cowen, and Piper Sandler are acting as joint book-running managers.
Why Is Monte Rosa Therapeutics Stock Skyrocketing Wednesday? - Monte Rosa Therapeutics (NASDAQ:GLUE)
Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) stock surged Wednesday following the release of positive interim data from a Phase 1 study of its experimental drug MRT-8102. The drug showed significant reductions in inflammation markers related to cardiovascular disease, with a favorable safety profile. The company anticipates further clinical advancements in its immunology and oncology pipelines in 2026.
Did Monte Rosa’s Interim MRT-8102 Data Reveal a Turning Point for Its Molecular Glue Platform (GLUE)?
Monte Rosa Therapeutics is presenting interim Phase 1 clinical trial results for MRT-8102, a key event for its molecular glue degrader platform. These early data will influence investor perception of the company's pipeline potential, especially its expansion beyond oncology. The outcome will be critical for shaping near-term expectations for the stock, which has seen volatile trading and significant returns.
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102
Monte Rosa Therapeutics announced positive interim data from its Phase 1 study of MRT-8102. The study showed significant reductions in CRP levels in subjects with CVD risk, with 94% achieving levels below 2 mg/L, demonstrating robust efficacy and a favorable safety profile. A Phase 2 study in ASCVD is planned for 2026 to further investigate MRT-8102's potential.
Monte Rosa Therapeutics Reports Positive Interim Data from Phase 1 Study of MRT-8102 in Reducing Inflammation in Cardiovascular Disease Risk Patients
Monte Rosa Therapeutics announced positive interim data from its Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader, showing significant reductions in inflammation for patients at cardiovascular disease risk. The drug achieved an 85% reduction in C-reactive protein (CRP) levels and demonstrated a favorable safety profile. The company plans to expand the ongoing GFORCE-1 study and initiate a Phase 2 study for atherosclerotic cardiovascular disease (ASCVD) in 2026.
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
Monte Rosa Therapeutics announced positive interim Phase 1 data for MRT-8102, showing significant reductions in C-reactive protein (CRP) levels in subjects with elevated cardiovascular disease (CVD) risk. The orally bioavailable molecular glue degrader of NEK7 rapidly and durably reduced systemic inflammation, achieving an 85% decrease in CRP and bringing 94% of participants below the 2 mg/L threshold associated with reduced CVD risk. The company plans to initiate a Phase 2 study in atherosclerotic cardiovascular disease (ASCVD) in 2026, highlighting the potential of MRT-8102 as a best-in-class therapeutic for chronic inflammatory diseases.
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced it will host a conference call and webcast on January 7, 2026, to present interim clinical results from the ongoing Phase 1 study of its NEK7-directed molecular glue degrader, MRT-8102. The presentation will include data from the CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk. The company is a clinical-stage biotechnology firm focused on developing molecular glue degrader (MGD)-based medicines.
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
Monte Rosa Therapeutics announced positive interim Phase 1 data for MRT-8102, a novel molecular glue degrader targeting NEK7, showing significant reductions in C-reactive protein (CRP) levels in individuals with elevated cardiovascular disease risk. The drug achieved an 85% reduction in CRP and brought 94% of participants below the 2 mg/L threshold associated with reduced CVD risk, alongside a favorable safety profile. The company plans to accelerate development in atherosclerotic cardiovascular disease with a Phase 2 study in 2026 and explore additional indications.
Early trial results for a new drug targeting heart disease risk go public
Monte Rosa Therapeutics (GLUE) will present interim Phase 1 clinical trial data for its NEK7-directed molecular glue degrader MRT-8102 on January 7, 2026. The presentation will include results from a proof-of-concept cohort in subjects with elevated cardiovascular disease risk. The stock experienced an 8.00% increase following this announcement, reflecting positive market sentiment regarding potential advancements in treating serious diseases.
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Monte Rosa Therapeutics will host a conference call and webcast on January 7, 2026, at 8:00 a.m. ET to present interim clinical results from the ongoing Phase 1 study of its NEK7-directed molecular glue degrader, MRT-8102. The presentation will include data from the Part 3 CRP proof-of-concept cohort for subjects with elevated cardiovascular disease risk. The company is developing highly selective molecular glue degrader medicines with three programs currently in clinical trials.
Monte Rosa to present interim results for NEK7-directed MGD By Investing.com
Monte Rosa Therapeutics (Nasdaq:GLUE) will present interim clinical results from its Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader, on a conference call and webcast. The announcement follows recent stock volatility and positive interim data from a separate clinical study for prostate cancer, which led to analyst upgrades and price target increases. The company utilizes its QuEEN discovery engine for MGD development and maintains a strong financial position, though InvestingPro estimates suggest it is slightly overvalued.
Squarepoint Ops LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE
Squarepoint Ops LLC recently acquired 178,136 shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) in Q2, valued at approximately $803,000, representing a 0.29% ownership stake. Other institutional investors have also adjusted their positions in the company, which currently has a "Hold" consensus rating and an average target price of $17.75 from analysts. Monte Rosa Therapeutics surpassed its most recent quarterly earnings and revenue estimates, boasts a market cap of $1.05 billion, and focuses on drug discovery using single-cell genomics and AI.
Monte Rosa Therapeutics (GLUE) Price Target Increased by 22.54% to 21.78
The average one-year price target for Monte Rosa Therapeutics (NasdaqGS:GLUE) has been increased by 22.54% to $21.78 per share, up from $17.78. This new target is an average of various analyst estimates, ranging from $16.16 to $28.88 per share, and represents a 40.18% increase from the last reported closing price of $15.54. Fund sentiment indicates a slight increase in institutional ownership, though total shares owned by institutions have decreased by 2.48%.
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE)
Two analysts have issued bullish sentiments on healthcare companies Novan (NOVN) and Monte Rosa Therapeutics (GLUE). Marc Frahm from TD Cowen maintained a Buy rating on Monte Rosa Therapeutics, while Wells Fargo also upgraded the stock to Buy, resulting in a Strong Buy consensus with a price target implying a slight upside.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Hold" by Brokerages
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received a consensus "Hold" rating from five research firms, with an average 12-month target price of $17.75. The company recently beat Q3 earnings and revenue estimates, reporting EPS of ($0.33) and revenue of $12.77 million. Institutional investors hold nearly 80% of the company's stock, with several firms acquiring new stakes.
